PDGF and MET pathways, SNAI2, POSTN, COL1A1, ASPN, MUC4, and others may be targets of choice to prevent the evolution of early stage of EMT in HNSCC tumors treated with anti-EGFR therapy. Here, MUC4 is linked to head and neck squamous cell carcinoma.